Discovery of Piragliatin—First Glucokinase Activator Studied in Type 2 Diabetic Patients-Reference-Cited by-同舟云学术

Discovery of Piragliatin—First Glucokinase Activator Studied in Type 2 Diabetic Patients

Published:2012-08 Issue:16 Volume:55 Page:7021-7036
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

Sarabu Ramakanth¹,Bizzarro Fred T.¹,Corbett Wendy L.¹,Dvorozniak Mark T.¹,Geng Wanping¹,Grippo Joseph F.¹,Haynes Nancy-Ellen¹,Hutchings Stanley¹,Garofalo Lisa¹,Guertin Kevin R.¹,Hilliard Darryl W.¹,Kabat Marek¹,Kester Robert F.¹,Ka Wang¹,Liang Zhenmin¹,Mahaney Paige E.¹,Marcus Linda¹,Matschinsky Franz M.²,Moore David¹,Racha Jagdish¹,Radinov Roumen¹,Ren Yi¹,Qi Lida¹,Pignatello Michael¹,Spence Cheryl L.¹,Steele Thomas¹,Tengi John¹,Grimsby Joseph¹

Affiliation:

1. Hoffmann-La Roche Inc., pRED, Pharma Research & Early Development, DTA Metabolism, 340 Kingsland Street, Nutley, New Jersey 07110, United States

2. Department of Biochemistry and Diabetes Center, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104, United States

Publisher

American Chemical Society (ACS)

Subject

Drug Discovery,Molecular Medicine

Link

https://pubs.acs.org/doi/pdf/10.1021/jm3008689

Reference19 articles.

1. Assessing the potential of glucokinase activators in diabetes therapy

2. Hormonal and dietary regulation of hepatic glucokinase